Evidence map›Paper›PMID 24553922›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2014

Proteomic survey reveals altered energetic patterns and metabolic failure prior to retinal degeneration.

Ana Griciuc, Michel J Roux, Juliane Merl, Angela Giangrande, Stefanie M Hauck, Liviu Aron, Marius Ueffing

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Flavin homeostasis in the mouse retina during aging and degeneration.The Journal of nutritional biochemistry · 2018
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Newly Identified Chemicals Preserve Mitochondrial Capacity and Decelerate Loss of Photoreceptor Cells in Murine Retinal Degeneration Models.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Ana GriciucResearch Unit Protein Science, Helmholtz Zentrum München (GmbH)-German Research Center for Environmental Health, D-85764 Neuherberg, Germany, Department of Translational Medicine and Neurogenetics and Department of Development and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104-INSERM U964-Université de Strasbourg, 67404 Illkirch, France, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, and Center for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, 72076 Tübingen, Germany.
Michel J Roux
Juliane Merl
Angela Giangrande
Stefanie M Hauck
Liviu Aron
Marius Ueffing
Center for Environmental Health · USHarvard University · USHelmholtz Zentrum München · DEImmungenetics (Germany) · DEInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inherited mutations that lead to misfolding of the visual pigment rhodopsin (Rho) are a prominent cause of photoreceptor neuron (PN) degeneration and blindness. How Rho proteotoxic stress progressively impairs PN viability remains unknown. To identify the pathways that mediate Rho toxicity in PNs, we performed a comprehensive proteomic profiling of retinas from Drosophila transgenics expressing Rh1(P37H), the equivalent of mammalian Rho(P23H), the most common Rho mutation linked to blindness in humans. Profiling of young Rh1(P37H) retinas revealed a coordinated upregulation of energy-producing pathways and attenuation of energy-consuming pathways involving target of rapamycin (TOR) signaling, which was reversed in older retinas at the onset of PN degeneration. We probed the relevance of these metabolic changes to PN survival by using a combination of pharmacological and genetic approaches. Chronic suppression of TOR signaling, using the inhibitor rapamycin, strongly mitigated PN degeneration, indicating that TOR signaling activation by chronic Rh1(P37H) proteotoxic stress is deleterious for PNs. Genetic inactivation of the endoplasmic reticulum stress-induced JNK/TRAF1 axis as well as the APAF-1/caspase-9 axis, activated by damaged mitochondria, dramatically suppressed Rh1(P37H)-induced PN degeneration, identifying the mitochondria as novel mediators of Rh1(P37H) toxicity. We thus propose that chronic Rh1(P37H) proteotoxic stress distorts the energetic profile of PNs leading to metabolic imbalance, mitochondrial failure, and PN degeneration and therapies normalizing metabolic function might be used to alleviate Rh1(P37H) toxicity in the retina. Our study offers a glimpse into the intricate higher order interactions that underlie PN dysfunction and provides a useful resource for identifying other molecular networks that mediate Rho toxicity in PNs.

Indexed as

AnimalsAnimals, Genetically ModifiedBlotting, WesternCaspase 9Coloring AgentsDrosophila melanogasterDrosophila ProteinsElectroretinographyEndoplasmic Reticulum-Associated DegradationEndoplasmic Reticulum StressEnergy MetabolismMass SpectrometryMicroscopy, ElectronMitochondriaMutationOxidative StressCaspase 9Coloring Agentsdark protein, DrosophilaDrosophila ProteinsProtein HydrolysatesRhodopsinTolonium ChlorideTOR Serine-Threonine KinasesmetabolismmitochondriamTORproteomicsretinitis pigmentosarhodopsin

Identifiers

PMID24553922
PMCPMC6608515
OpenAlexW1970663741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.